H.C. Wainwright Starts Generate Biomedicines (GENB) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/14/2026
- Nasdaq ends sharply lower as hot inflation data stirs rate-hike worries
- Oil prices gain on attacks in Saudi Arabia, Iran's new tactics to target tankers
- U.S. consumer prices rise by 3.7% year-on-year in September
- Bank of America stock falls on earnings miss
- Netflix cuts 1,000 jobs as streaming giant seeks to boost engagement
Tweet
Share
E-mailGet Alerts GENB Hot Sheet
Price: $12.52 +2.12%
Rating Summary:
6 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 12 | New: 54
Rating Summary:
6 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 12 | New: 54
Join SI Premium – FREE
H.C. Wainwright initiates coverage on Generate Biomedicines (NASDAQ: GENB) with a Buy rating and a price target of $16.00.
For an analyst ratings summary and ratings history on Generate Biomedicines click here. For more ratings news on Generate Biomedicines click here.
Shares of Generate Biomedicines closed at $11.41 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Apple to launch AI features in China in December after regulatory delay - Bloomberg
- Infinity Natural Resources reports $64.4M derivative loss in Q3 2026
- Jefferies Starts Black Hills Corp (BKH) at Buy
Create E-mail Alert Related Categories
New CoverageRelated Entities
Maynard Um, H.C. Wainwright, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
